U.S., Feb. 15 -- ClinicalTrials.gov registry received information related to the study (NCT06828055) titled 'VK2735 for Weight Management Phase 2 (Venture Oral Dosing)' on Feb. 10.
Brief Summary: This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI >=30 kg/m2) or who are overweight (BMI >=27 kg/m2) with at least one weight-related co-morbid condition.
VK2735 or matched placebo will be administered once daily.
Study Start Date: Dec. 18, 2024
Study Type: INTERVENTIONAL
Condition:
Weight Loss
Intervention:
DRUG: Placeb...